- Home
- KBH vs DNLI Comparison
KBH vs DNLI Comparison
Compare KBH & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBH | DNLI |
|---|---|---|
| Founded | 1957 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KBH | DNLI |
|---|---|---|
| Price | $56.72 | $23.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $56.17 | $34.33 |
| AVG Volume (30 Days) | 995.4K | ★ 1.9M |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $4,547,002,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.23 | $408.85 |
| P/E Ratio | $57.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.03 | $12.58 |
| 52 Week High | $68.71 | $27.30 |
Technical Indicators
Market Signals| Indicator | KBH | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 45.21 |
| Support Level | $55.49 | $18.27 |
| Resistance Level | $56.64 | $23.27 |
| Average True Range (ATR) | 1.90 | 1.38 |
| MACD | -0.39 | -0.39 |
| Stochastic Oscillator | 38.99 | 17.58 |
Price Performance
Historical ComparisonAbout KBH KB Home
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.